{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T19:13:46Z","timestamp":1781291626748,"version":"3.54.1"},"reference-count":84,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Department of Defense Breast Cancer Research Program","award":["W81XWH-19-1-0113"],"award-info":[{"award-number":["W81XWH-19-1-0113"]}]},{"name":"Manhasset Women's Coalition Against Breast Cancer","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"LIBH","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100000893","name":"Simons Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100000893","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MSTP","award":["T32-GM008444"],"award-info":[{"award-number":["T32-GM008444"]}]},{"name":"Northwell-Cold Spring Harbor Collaborative Research Grant","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Breast Cancer Research Foundation Convergence Team","award":["2015-001"],"award-info":[{"award-number":["2015-001"]}]},{"name":"Breast Cancer Research Foundation Convergence Team","award":["SU2C-BCRF"],"award-info":[{"award-number":["SU2C-BCRF"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,12,4]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cancer\u2013testis (CT) genes are targets for tumor antigen-specific immunotherapy given that their expression is normally restricted to the immune-privileged testis in healthy individuals with aberrant expression in tumor tissues. While they represent targetable germ tissue antigens and play important functional roles in tumorigenesis, there is currently no standardized approach for identifying clinically relevant CT genes. Optimized algorithms and validated methods for accurate prediction of reliable CT antigens (CTAs) with high immunogenicity are also lacking.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Sequencing data from the Genotype-Tissue Expression (GTEx) and The Genomic Data Commons (GDC) databases was used for the development of a bioinformatic pipeline to identify CT exclusive genes. A CT germness score was calculated based on the number of CT genes expressed within a tumor type and their degree of expression. The impact of tumor germness on clinical outcome was evaluated using healthy GTEx and GDC tumor samples. We then used a triple-negative breast cancer mouse model to develop and test an algorithm that predicts epitope immunogenicity based on the identification of germline sequences with strong major histocompatibility complex class I (MHCI) and MHCII binding affinities. Germline sequences for CT genes were synthesized as long synthetic peptide vaccines and tested in the 4T1 triple-negative model of invasive breast cancer with Poly(I:C) adjuvant. Vaccine immunogenicity was determined by flow cytometric analysis of in vitro and in vivo T-cell responses. Primary tumor growth and lung metastasis was evaluated by histopathology, flow cytometry and colony formation assay.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We developed a new bioinformatic pipeline to reliably identify CT exclusive genes as immunogenic targets for immunotherapy. We identified CT genes that are exclusively expressed within the testis, lack detectable thymic expression, and are significantly expressed in multiple tumor types. High tumor germness correlated with tumor progression but not with tumor mutation burden, supporting CTAs as appealing targets in low mutation burden tumors. Importantly, tumor germness also correlated with markers of antitumor immunity. Vaccination of 4T1 tumor-bearing mice with Siglece and Lin28a antigens resulted in increased T-cell antitumor immunity and reduced primary tumor growth and lung metastases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our results present a novel strategy for the identification of highly immunogenic CTAs for the development of targeted vaccines that induce antitumor immunity and inhibit metastasis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2023-007935","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T13:15:57Z","timestamp":1703250957000},"page":"e007935","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Identification of pan-cancer\/testis genes and validation of therapeutic targeting in triple-negative breast cancer: Lin28a-based and Siglece-based vaccination induces antitumor immunity and inhibits metastasis"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct02166905","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00071981","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01213472","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02650986","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01967823","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01522820","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03093350","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02015416","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jason A","family":"Carter","sequence":"first","affiliation":[{"name":"Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA"},{"name":"Stony Brook University, Stony Brook, New York, USA"},{"name":"Department of Surgery, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharati","family":"Matta","sequence":"additional","affiliation":[{"name":"Northwell Health Feinstein Institutes for Medical Research, Manhasset, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1479-1416","authenticated-orcid":false,"given":"Jenna","family":"Battaglia","sequence":"additional","affiliation":[{"name":"Northwell Health Feinstein Institutes for Medical Research, Manhasset, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carter","family":"Somerville","sequence":"additional","affiliation":[{"name":"Northwell Health Feinstein Institutes for Medical Research, Manhasset, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D","family":"Harris","sequence":"additional","affiliation":[{"name":"Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA"},{"name":"Lyell Immunopharma, South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"LaPan","sequence":"additional","affiliation":[{"name":"Northwell Health Feinstein Institutes for Medical Research, Manhasset, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurinder S","family":"Atwal","sequence":"additional","affiliation":[{"name":"Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, USA"},{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6766-4352","authenticated-orcid":false,"given":"Betsy J","family":"Barnes","sequence":"additional","affiliation":[{"name":"Northwell Health Feinstein Institutes for Medical Research, Manhasset, New York, USA"},{"name":"Departments of Pediatrics and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"key":"2025100305182739000_11.12.e007935.1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3682"},{"key":"2025100305182739000_11.12.e007935.2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4971"},{"key":"2025100305182739000_11.12.e007935.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00346-0"},{"key":"2025100305182739000_11.12.e007935.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00460-2"},{"key":"2025100305182739000_11.12.e007935.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.053"},{"key":"2025100305182739000_11.12.e007935.6","doi-asserted-by":"publisher","DOI":"10.1038\/nature22991"},{"key":"2025100305182739000_11.12.e007935.7","doi-asserted-by":"publisher","DOI":"10.1038\/nature23003"},{"key":"2025100305182739000_11.12.e007935.8","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa3828"},{"key":"2025100305182739000_11.12.e007935.9","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","article-title":"Actively personalized vaccination trial for newly diagnosed glioblastoma","volume":"566","author":"Hilf","year":"2019","journal-title":"Nature"},{"key":"2025100305182739000_11.12.e007935.10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase IB glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"2025100305182739000_11.12.e007935.11","doi-asserted-by":"publisher","DOI":"10.1038\/nature13387"},{"key":"2025100305182739000_11.12.e007935.12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1509"},{"key":"2025100305182739000_11.12.e007935.13","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/s43018-021-00246-0","article-title":"Targeting public neoantigens for cancer immunotherapy","volume":"2","author":"Pearlman","year":"2021","journal-title":"Nat Cancer"},{"key":"2025100305182739000_11.12.e007935.14","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1517\/14712598.2010.485188","article-title":"Cancergermline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment","volume":"10","author":"Gjerstorff","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"2025100305182739000_11.12.e007935.15","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4694"},{"key":"2025100305182739000_11.12.e007935.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2019.02.008"},{"key":"2025100305182739000_11.12.e007935.17","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-065X.2002.18803.x"},{"key":"2025100305182739000_11.12.e007935.18","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25661-w","article-title":"DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation","volume":"12","author":"Batra","year":"2021","journal-title":"Nat Commun"},{"key":"2025100305182739000_11.12.e007935.19","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms9840","article-title":"Comprehensive functional characterization of cancer-Testis antigens defines obligate participation in multiple hallmarks of cancer","volume":"6","author":"Maxfield","year":"2015","journal-title":"Nat Commun"},{"key":"2025100305182739000_11.12.e007935.20","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/pros.21214","article-title":"Expression of cancer\/testis antigens in prostate cancer is associated with disease progression","volume":"70","author":"Suyama","year":"2010","journal-title":"Prostate"},{"key":"2025100305182739000_11.12.e007935.21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1544"},{"key":"2025100305182739000_11.12.e007935.22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005723","article-title":"Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers","volume":"5","author":"Rousseaux","year":"2013","journal-title":"Sci Transl Med"},{"key":"2025100305182739000_11.12.e007935.23","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.cell.2018.03.026","article-title":"Cancer-germline antigen expression discriminates clinical outcome to CTLA-4 blockade","volume":"173","author":"Shukla","year":"2018","journal-title":"Cell"},{"key":"2025100305182739000_11.12.e007935.24","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0088"},{"key":"2025100305182739000_11.12.e007935.25","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2217\/imt-2017-0179","article-title":"Cancer testis antigens as immunogenic and oncogenic targets in breast cancer","volume":"10","author":"Mahmoud","year":"2018","journal-title":"Immunotherapy"},{"key":"2025100305182739000_11.12.e007935.26","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153875","article-title":"Cancer-Testis antigens in triple-negative breast cancer: role and potential utility in clinical practice","volume":"13","author":"Lam","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025100305182739000_11.12.e007935.27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017876","article-title":"Multiple cancer\/Testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers","volume":"6","author":"Chen","year":"2011","journal-title":"PLoS One"},{"key":"2025100305182739000_11.12.e007935.28","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkn673"},{"key":"2025100305182739000_11.12.e007935.29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810777105"},{"key":"2025100305182739000_11.12.e007935.30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0502583102"},{"key":"2025100305182739000_11.12.e007935.31","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-3725"},{"key":"2025100305182739000_11.12.e007935.32","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2653"},{"key":"2025100305182739000_11.12.e007935.33","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2764"},{"key":"2025100305182739000_11.12.e007935.34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21254-9"},{"key":"2025100305182739000_11.12.e007935.35","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10499","article-title":"Systematic identification of genes with a cancer-Testis expression pattern in 19 cancer types","volume":"7","author":"Wang","year":"2016","journal-title":"Nat Commun"},{"key":"2025100305182739000_11.12.e007935.36","doi-asserted-by":"crossref","first-page":"92966","DOI":"10.18632\/oncotarget.21715","article-title":"Genome-wide identification of cancer\/Testis genes and their association with prognosis in a pan-cancer analysis","volume":"8","author":"da Silva","year":"2017","journal-title":"Oncotarget"},{"key":"2025100305182739000_11.12.e007935.37","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"Netmhcpan-4.1 and Netmhciipan-4.0: improved predictions of MHC antigen presentation by concurrent motif Deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"2025100305182739000_11.12.e007935.38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3175"},{"key":"2025100305182739000_11.12.e007935.39","doi-asserted-by":"publisher","DOI":"10.1093\/NAR\/GKAB1049"},{"key":"2025100305182739000_11.12.e007935.40","doi-asserted-by":"publisher","DOI":"10.1007\/s12064-013-0178-3"},{"key":"2025100305182739000_11.12.e007935.41","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa0355"},{"key":"2025100305182739000_11.12.e007935.42","doi-asserted-by":"publisher","DOI":"10.1038\/s41596&ndash;019&ndash;0128&ndash;8"},{"key":"2025100305182739000_11.12.e007935.43","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31750-1","article-title":"Transcriptomic diversity in human medullary thymic epithelial cells","volume":"13","author":"Carter","year":"2022","journal-title":"Nat Commun"},{"key":"2025100305182739000_11.12.e007935.44","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.125377","article-title":"Keratinocyte growth factor impairs human thymic recovery from lymphopenia","volume":"5","author":"Coles","year":"2019","journal-title":"JCI Insight"},{"key":"2025100305182739000_11.12.e007935.45","doi-asserted-by":"crossref","DOI":"10.1038\/nbt0816-888d","article-title":"Erratum: near-optimal probabilistic RNA-Seq quantification","volume":"34","author":"Bray","year":"2016","journal-title":"Nat Biotechnol"},{"key":"2025100305182739000_11.12.e007935.46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1607591"},{"key":"2025100305182739000_11.12.e007935.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.03.023"},{"key":"2025100305182739000_11.12.e007935.48","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.21105\/joss.01317","article-title":"Lifelines: survival analysis in python","volume":"4","author":"Davidson-Pilon","year":"2019","journal-title":"JOSS"},{"key":"2025100305182739000_11.12.e007935.49","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.4324"},{"key":"2025100305182739000_11.12.e007935.50","doi-asserted-by":"publisher","DOI":"10.1002\/pro.4218"},{"key":"2025100305182739000_11.12.e007935.51","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/978-1-60761-869-0_29","article-title":"Immunoprivileged sites: the testis","volume":"677","author":"Fijak","year":"2011","journal-title":"Methods Mol Biol"},{"key":"2025100305182739000_11.12.e007935.52","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2014.38"},{"key":"2025100305182739000_11.12.e007935.53","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2025100305182739000_11.12.e007935.54","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.2174\/1381612821666141211154707","article-title":"Cancer\/Testis antigens trigger epithelial-mesenchymal transition and genesis of cancer stem-like cells","volume":"21","author":"Yang","year":"2015","journal-title":"Curr Pharm Des"},{"key":"2025100305182739000_11.12.e007935.55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1370"},{"key":"2025100305182739000_11.12.e007935.56","doi-asserted-by":"publisher","DOI":"10.1038\/nature11412"},{"key":"2025100305182739000_11.12.e007935.57","doi-asserted-by":"publisher","DOI":"10.1126\/science.1251102"},{"key":"2025100305182739000_11.12.e007935.58","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"523","author":"Kreiter","year":"2015","journal-title":"Nature"},{"key":"2025100305182739000_11.12.e007935.59","doi-asserted-by":"publisher","DOI":"10.1038\/nature24462"},{"key":"2025100305182739000_11.12.e007935.60","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41586-022-04735-9","article-title":"Neoantigen quality predicts immunoediting in survivors of pancreatic cancer","volume":"606","author":"\u0141uksza","year":"2022","journal-title":"Nature"},{"key":"2025100305182739000_11.12.e007935.61","doi-asserted-by":"publisher","DOI":"10.1038\/nature24473"},{"key":"2025100305182739000_11.12.e007935.62","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30700-9"},{"key":"2025100305182739000_11.12.e007935.63","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0345-7","article-title":"Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis","volume":"6","author":"Lattanzi","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2025100305182739000_11.12.e007935.64","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910630622"},{"key":"2025100305182739000_11.12.e007935.65","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21264"},{"key":"2025100305182739000_11.12.e007935.66","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-5193-9","article-title":"A phase II trial of recombinant MAGE-A3 protein with immunostimulant As15 in combination with high-dose Interleukin-2 (Hdil2) induction therapy in metastatic Melanoma","volume":"18","author":"McQuade","year":"2018","journal-title":"BMC Cancer"},{"key":"2025100305182739000_11.12.e007935.67","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-10-141","article-title":"Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-Testis antigens","volume":"10","author":"Kono","year":"2012","journal-title":"J Transl Med"},{"key":"2025100305182739000_11.12.e007935.68","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3892\/ijo.2013.2242","article-title":"Phase I clinical trial of peptide vaccination with Urlc10 and Vegfr1 EPITOPE peptides in patients with advanced gastric cancer","volume":"44","author":"Higashihara","year":"2014","journal-title":"Int J Oncol"},{"key":"2025100305182739000_11.12.e007935.69","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-013-0258-6"},{"key":"2025100305182739000_11.12.e007935.70","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0202"},{"key":"2025100305182739000_11.12.e007935.71","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-12-61","article-title":"Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer","volume":"12","author":"Aruga","year":"2014","journal-title":"J Transl Med"},{"key":"2025100305182739000_11.12.e007935.72","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3592"},{"key":"2025100305182739000_11.12.e007935.73","doi-asserted-by":"crossref","DOI":"10.4161\/onci.27010","article-title":"Immunological responses to a multi-peptide vaccine targeting cancer-Testis antigens and VEGFRs in advanced Pancreatic cancer patients","volume":"2","author":"Okuyama","year":"2013","journal-title":"Oncoimmunology"},{"key":"2025100305182739000_11.12.e007935.74","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30254-7"},{"key":"2025100305182739000_11.12.e007935.75","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00099-1"},{"key":"2025100305182739000_11.12.e007935.76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211437"},{"key":"2025100305182739000_11.12.e007935.77","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1860"},{"key":"2025100305182739000_11.12.e007935.78","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.2009.02355.x"},{"key":"2025100305182739000_11.12.e007935.79","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.canlet.2013.03.010","article-title":"Blockade of PD-1\/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in Hu-SCID mice","volume":"336","author":"Ge","year":"2013","journal-title":"Cancer Lett"},{"key":"2025100305182739000_11.12.e007935.80","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/bioinformatics\/btz619","article-title":"Using multiple measurements of tissue to estimate Subject- and cell-type-specific gene expression","volume":"36","author":"Wang","year":"2020","journal-title":"Bioinformatics"},{"key":"2025100305182739000_11.12.e007935.81","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btq109"},{"key":"2025100305182739000_11.12.e007935.82","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4331\/wjbc.v13.i2.35","article-title":"LIN28A: a multifunctional versatile molecule with future therapeutic potential","volume":"13","author":"Wu","year":"2022","journal-title":"World J Biol Chem"},{"key":"2025100305182739000_11.12.e007935.83","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-28438-x","article-title":"Lin28B-high breast cancer cells promote immune suppression in the lung pre-metastatic niche via exosomes and support cancer progression","volume":"13","author":"Qi","year":"2022","journal-title":"Nat Commun"},{"key":"2025100305182739000_11.12.e007935.84","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2010.200"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-007935","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:18:39Z","timestamp":1759493919000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-007935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":84,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,22]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/jitc-2023-007935"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-007935","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}